Nov 13 (Reuters) - Mikael Dolsten, Pfizer's (PFE.N), opens new tab former research and development chief, has withdrawn his candidacy for Novo Nordisk's (NOVOb.CO), opens new tab board, citing ...
Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told his company's rival to put its money where its mouth is. “Novo Nordisk and Pfizer ...
Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback